Thera-SAbDab

UTOMILUMAB

>   Structural Summary
TherapeuticUtomilumab
TargetTNFRSF9
Heavy ChainEVQLVQSGAEVKKPGESLRISCKGSGYSFSTYWISWVRQMPGKGLEWMGKIYPGDSYTNYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARGYGIFDYWGQGTLVTVSS
Light ChainSYELTQPPSVSVSPGQTASITCSGDNIGDQYAHWYQQKPGQSPVLVIYQDKNRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCATYTGFGSLAVFGGGTKLTVL
100% seqID Fv Structure6a3w [Fvs: AB, DE, GH, JK], 6mi2 [Fvs: AB, DE]
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG2
Highest Clinical Trial (June '19)Phase-II
Estimated Status (June '19)Active
Recorded Developmental TechnologyMorphoSys HuCAL Phage Display
INN Year Proposed2016
INN Year Recommended2017
Companies InvolvedDana-Farber Cancer Institute, Immatics US, Kite Pharma, Kyowa Hakko Kirin, M. D. Anderson Cancer Center, Pfizer
Conditions Approvedna
Conditions ActiveBreast cancer, Oropharyngeal cancer, Solid tumours, B-cell lymphoma, Diffuse large B cell lymphoma, Colorectal cancer, Follicular lymphoma, Ovarian cancer
Conditions DiscontinuedNon-Hodgkin's lymphoma
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]